Intrexon intends to employ its integrated synthetic biology platforms to engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs.
http://www.biospace.com/news_story.aspx?StoryID=319260&full=1
http://www.biospace.com/news_story.aspx?StoryID=319260&full=1
No comments:
Post a Comment